Antibody phage display technology has revolutionized the field of immunovirology with its application in viral disease diagnostics and antiviral therapy.

The use of combinatorial libraries has given researchers unprecedented control over the expression of the acquired immune system. While many researchers have primarily focused on the diagnostic potential of rAbs in veterinary medicine, their immense therapeutic and immunoprophylactic potential has been largely ignored. Despite advancements in antibody engineering, experimental therapeutics remains a challenge due to the small size, low in vivo half-life, rapid clearance, and low stability of scFv antibodies. However, PEGylation and conjugation with certain drugs and toxins have helped overcome some of these issues. Additionally, there is a vast potential for exploring the diagnostic and therapeutic potential of diverse antibody repertoires amongst different species in relation to animal diseases. Advancements in targeted delivery of rAbs to various compartments of the animal body, such as the gut, brain, or intracellular cytosolic compartment, could have a huge impact on the efficacy of antibody therapeutics. Overall, the implementation of antibody phage display technology is opening new dimensions in immunovirology in terms of pathogenesis, diagnosis, and therapeutics.

Alpha Lifetech Inc. offers a broad range of services for the development and production of monoclonal antibodies. We can provide custom services from recombinant mAbs, humanized antibodies, chimeric antibodies, nanoantibodies (diabody, VHH) to single-domain antibody.